BRCA1 Gene Mutation: Clinical Trials

3 trials for BRCA1 Gene Mutation, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 3

Follow BRCA1 Gene Mutation: new trials by email Literature Review of BRCA1 Gene Mutation trials Research Report on BRCA1 Gene Mutation

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Olaparib, Durvalumab, and Tremelimumab in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube or Primary Peritoneal Cancer With BRCA1 or BRCA2 Mutation
Durvalumab, Laboratory Biomarker Analysis, Olaparib - BRCA1 Gene Mutation, BRCA2 Gene Mutation
Phase 2CompletedRoswell Park Cancer Institute402017-06-292024-11-19
Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer
Laboratory Biomarker Analysis, Pharmacological Study, Talazoparib - ATM Gene Mutation, ATR Gene Mutation
Phase 2CompletedSWOG Cancer Research Network512017-03-032021-06-23
ABT-888 and Temozolomide for Metastatic Breast Cancer and BRCA1/2 Breast Cancer
ABT-888, temozolomide - Breast Cancer, Metastatic Breast Cancer
Phase 2CompletedSteven J Isakoff, MD, PhD632009-11-012025-03-14

Narrower conditions

Breast Neoplasms (1)  ·  Fallopian Tube Neoplasms (1)  ·  Ovarian Neoplasms (1)

Broader conditions

Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Adnexal Diseases (1)  ·  Breast Diseases (1)  ·  Endocrine Gland Neoplasms (1)  ·  Endocrine System Diseases (1)  ·  Fallopian Tube Diseases (1)  ·  Female Urogenital Diseases (1)  ·  Female Urogenital Diseases and Pregnancy Complications (1)  ·  Genital Diseases (1)  ·  Genital Diseases, Female (1)  ·  Genital Neoplasms, Female (1)  ·  Gonadal Disorders (1)  ·  Ovarian Diseases (1)  ·  Skin Diseases (1)

Interventions

Disulfides (1)  ·  Immunoglobulin G (1)  ·  Temozolomide (1)  ·  durvalumab (1)  ·  olaparib (1)  ·  talazoparib (1)  ·  tremelimumab (1)  ·  veliparib (1)

Sponsors

Roswell Park Cancer Institute (1)  ·  SWOG Cancer Research Network (1)  ·  Steven J Isakoff, MD, PhD (1)

Countries

United States (3)  ·  Canada (1)

Top investigators

Emese Zsiros (1)  ·  Steven Isakoff, MD, PhD (1)  ·  Vassiliki Papadimitrakopoulou (1)

Results publications

PMID 34417675

NIH funding

U10CA180888 (1)